Ascendia Pharma CEO Presents on Gene Therapy Drug Delivery Technologies at SAPA Event

Ascendia Pharmaceuticals CEO Jim Huang, PhD, presented at the Greater Philadelphia Chapter of the Sino-American Pharmaceutical Professionals Association (SAPA) event. The chapter, also known as SAPA-GP, held its inaugural @Philly Cell and Gene Therapy Annual Conference this past weekend in King of Prussia, PA.

The two-day conference raised awareness of the cell and gene therapy ecosystem in the greater Philadelphia area. It also served as a networking opportunity for attendees. Dr. Huang presented Drug Delivery Technologies for Gene Therapy on Saturday, June 18 at the conference room in the Sheraton Valley Forge Hotel. The presentation included discussion on how nanotechnologies, including Ascendia’s proprietary EmulSol^®, AmorSol^®, and NanoSol^®, can be used to develop formulations to aid biologics successfully pass through the drug pipeline.

Dr. Huang has previously presented at SAPA events. Most recently, he spoke at the 2022 SAPA Scientific Symposium: Exploring New Frontiers in Science and Technology for Future Therapeutics. Dr. Huang’s session was entitled Nanotechnology platforms for use in drug discovery and development.

Ascendia Pharmaceuticals is a sponsor of SAPA, which is headquartered in the center of the New Jersey pharmaceutical corridor. Most SAPA members are from large and mid-sized pharmaceutical and biotech companies throughout the United States.

Contact us today to learn how Ascendia’s team can help you develop technologies for gene therapy.